Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581885 | 0.80 | NPC1 (0.44) | NPC1RAB9ATP53KMT2AKDM4E | |
| SCHEMBL3580926 | 0.80 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| SCHEMBL3583083 | 0.80 | NPSR1 (0.33) | ESR2GAAKDM4EMAPT | |
| SCHEMBL3577116 | 0.79 | EGFR (0.36) | TP53MEN1KMT2AGAAMAPT | |
| SCHEMBL3578503 | 0.77 | GAA (0.31) | MEN1KMT2AGAAMAPT | |
| SCHEMBL2347440 | 0.74 | NPC1 (0.39) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL3576492 | 0.74 | NPC1 (0.39) | NPC1RAB9ATP53KMT2AKDM4E | |
| SCHEMBL2348136 | 0.70 | DRD1 (0.43) | NPC1RAB9ASMN1; SMN2MAPK1GSK3B | |
| SCHEMBL15733761 | 0.68 | ESR1 (0.32) | ESR2 | |
| SCHEMBL3576850 | 0.68 | CNR2 (0.43) | MAPK1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022526-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-28 | — | — | US | claimed |
| EP-2121628-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2009-11-25 | — | — | EP | claimed |
| WO-2008089934-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-07-31 | — | — | WO | claimed |
| US-20100022526-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2121628-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008089934-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022526-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | CYP4Z1, CYP1A2, CYP1A1 | NPC1 3839/4885RAB9A 2942/4885SMN1; SMN2 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.